Lung cancer
Conditions
Interventions
Experimental group:Preoperative cryoablation combined with immunotherapy and chemotherapy treatment
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Age >= 18 years old or = 1%); 5) According to the surgeon's assessment, the total lung function can withstand the proposed lung resection surgery; 6) ECOG PS score 0-1 points; 7) According to the Response Evaluation Criteria for Solid Tumors (RECIST 1.1), there must be at least one measurable lesion; 8) There has been no targeted anti-tumor treatment in the past; 9) Having good organ function; 10) Women of childbearing age must undergo a serum pregnancy test within 3 days before their first medication, and the result must be negative; 11) The subjects are willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study; 12) Can understand and be willing to sign a written informed consent document approved by the ethics committee.
Exclusion criteria
Exclusion criteria: 1) The compound confirmed by pathology contains components of small cell lung cancer; 2) Due to anatomical reasons of tumors, it is difficult to undergo cryotherapy; 3) Severe coagulation dysfunction or the use of anticoagulants, antiplatelet agents, anti angiogenic drugs, etc., which cannot be stopped in the short term; 4) Previously received chest radiation therapy or immunotherapy; 5) Active autoimmune diseases that require systemic treatment within 2 years prior to enrollment; Alternative therapies (such as thyroid hormones, insulin, or physiological corticosteroids for the treatment of adrenal or pituitary dysfunction) are not considered systemic treatments; 6) Insufficient lung function to tolerate surgery; 7) Known history of HIV infection (i.e. HIV 1/2 antibody positive); 8) Untreated active hepatitis B or active hepatitis C virus infection; 9) Pregnant or lactating women; 10) Any serious or uncontrollable systemic illness, including mental illness;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TNM staging reduction rate;Complete pathological remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Main pathological remission rate;Disease-free survival period;Objective response rate;R0 resection rate; | — |
Countries
China
Contacts
Public ContactHaitao Huang, Cheng Ji
The First Affiliated Hospital of Soochow University
Outcome results
None listed